The safety of our children is a sacred obligation we strive to preserve. Anything or anyone that harms them becomes the object of our distrust and potential wrath. I want to raise the possibility that psychiatry, for all its accomplished … Full Article →
Prior admissions with stimulant disorder, but not a prior cannabis disorder diagnosis, are a negative prognostic sign in first-episode psychosis according to new research in the British Journal of Psychiatry. “Young people with substance comorbidities may have both the best and worst of outcomes, depending on whether problematic substance use is discontinued,” the authors note.
According to the University of South Dakota’s The Volante, “In 1993, about four percent of American college students used prescription drugs for nonmedical uses, according to a March 2007 study in the journal “Addiction”. By 2001, that number had increased to 10 percent. Then, in 2010, that number spiked to 27 percent.”
There’s a growing (and soon to be quickly growing) group of us who are not therapists or psychiatrists but who offer “coaching,” connection and support. We offer this support to those coming off psychiatric drugs, or who would like to, or are opting to not go on in the first place but are facing pressure to. Most of us are psychiatric survivors so a lot of our knowledge and information is from firsthand experience. Others may have never been on psychiatric drugs but know a lot about the ins and outs of withdrawal through close association with those who have. Full Article →
Dr. Claudia Gold of Boston.com comments on the recent research finding that “thoughts of suicide, sexual difficulties and emotional numbness as a result of anti-depressants may be more widespread than previously thought.”
Lawyers for Johnson & Johnson took the stand in Arkansas today, a final effort at convincing the Arkansas Supreme Court to overturn a jury’s award of $1.2 billion for off-label marketing of Risperdal. J&J plans to argue that the award is excessive, and that the company was exercising its right to free speech in promoting the drug. The attorneys general of 35 states have filed a brief urging the court to uphold the verdict.
Animal studies have raised concerns about SSRIs and ADHD stimulants inducing lasting abnormalities in the developing brain. Researchers from the University of Amsterdam are now planning a series of three studies on the effects of Psychotropic drugs on Developing brains (the ePOD study). The present their proposed protocol and rationale in BMC Psychiatry.
Like so many others, I have wanted to embrace the idea that research supports such beliefs as “ADHD is a chronic disease plaguing children”, and/or “Bigfoot exists”. I mean, who wouldn’t? We assume that research is based on sound evidence; information we can trust. Who wouldn’t want to believe evidence that there is a simple medical explanation for those annoying behaviors exhibited by children in the process of developing into responsible young adults? Full Article →
There’s an interesting February 11, 2014, article on Peter Breggin’s website: $1.5 Million Award in Child Tardive Dyskinesia Malpractice. Apparently the individual in Dr. Breggin’s paper was diagnosed with autism as a child and was prescribed SSRI’s before the age of seven. The SSRI’s caused some deterioration in the child’s behavior and mental condition, to combat which his first psychiatrist prescribed Risperdal (risperidone). Subsequently a second psychiatrist added Zyprexa (olanzapine) to the cocktail. Both Risperdal and Zyprexa are neuroleptics (euphemistically known in psychiatric circles as antipsychotics), and are known to cause tardive dyskinesia. Full Article →
A report on antidepressant consumption released on 18 February 2014 by the OECD shows huge increases in prescribing of the drugs across most countries. According to the report a key factor driving this increase is the expansion of the off label use of the drugs for a vastly increased number of indications. While this may not seem like news, I think it warrants some analysis because I think what we are seeing is something more complex than simple market expansion. Full Article →
A trial of a new process of identifying drugs that can disrupt sex hormones singled out Paxil from 446 common drugs as having a weak estrogenic effect that could promote the growth of breast tumors in women. The study may shed light on previous studies that found women taking Paxil were more likely than those taking other antidepressants to die of breast cancer when also taking tamoxifen to prevent breast cancer recurrence.
Adverse effects of antidepressants, including sexual difficulties and emotional numbing, apathy, suicidality and withdrawal effects may be more frequent than previously reported, according to research published yesterday in Psychiatry Research. John Read, et al., surveyed 1,829 adults – the largest sample surveyed to date – who had been prescribed antidepressants in the last five years. Emotional “side-effects” were reported by more than 50%.
A Hong Kong study links short “Duration of Untreated Psychosis” (DUP) to better long-term outcome. The authors propose that factors linked to long DUP may be implicated in poor recovery, and so may provide targets for intervention. Other than specifying that enrollees had taken antipsychotics for a week or less (1/2 being medication naive), treatment modality in this study was unspecified.
Recently, I have been the target of much wooing by my local Sunovion rep. I think he leaves messages for me almost weekly and he sends me missives – glossy brochures and reprints from major psychiatric journal. What is the subject of this attention? The drug – lurasidone (Latuda). Full Article →
My last blog raised issues about the involvement of Shire Pharmaceuticals in lobbying for the inclusion of mandatory screening of children for ADHD in a bill before the UK parliament. It questioned the involvement of key opinion leaders including MEP … Full Article →
Steven Morgan discusses his transformative journey from chronic “patient” to leading mental health advocate. Steven has been working in peer support and helping to create alternatives to traditional mental health services for the past decade. In 2013, he became Operations Manager for Intentional Peer Support, where he brings a passion for creating instruments of social change, a love of organizational development, and a belief in the transformative power of community. On full moons he enjoys writing, playing music, woodworking, and taking long long walks. This is latest in a series of testimonials featured on MadInAmerica.com produced by the Open Paradigm Project - @Open_Paradigm on Twitter. (more…)
Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating.
Connecticut continues to block public access to information on homicide investigations, according to the Connecticut News Times, an effort that began with concerns over the shooting in Sandy Hook by Adam Lanza in December of 2012. Such disclosure would “cause a lot of people to stop taking their medications,” said CT Assistant Attorney General Patrick B. Kwanashie, speaking at a Freedom of Information Act hearing called by Ablechild last year.
In 2004, a patient was given an experimental antipsychotic called bifeprunox and died of hepatorenal failure nine days later. But the sponsor apparently did not investigate the death for three years. In late 2007 the sponsor issued a safety alert and suspended all bifeprunox studies. This is where things get interesting. Full Article →
An important study was headlined on MIA this week. The study examined the effectiveness of cognitive behavioral therapy (CBT) to treat the symptoms of people labeled with a diagnosis of schizophrenia and related conditions who had elected to not take neuroleptic drugs. Full Article →
In “the first randomised trial of cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs”, researchers from the U.K. found cognitive therapy without medication was both safe and effective in reducing symptoms.” “Additionally, cognitive therapy significantly improved personal and social functioning and some dimensions of delusional beliefs (cognitive) and voice hearing (cognitive and physical).” The study appears today in The Lancet, with a commentary calling the study “ground-breaking evidence” for an alternative.
Since I am new on Mad in America, I will tell you; my mission is to debunk the ADHD diagnosis. My goal is to add common sense to a world where drugging kids for acting like kids is all the rage. When discussing ADHD with concerned adults I share how little is required to earn a diagnosis of ADHD. Learning just how non-scientific the diagnosis actually is, for many, is a shocking discovery. Full Article →